Russell Skibsted

Russell Skibsted discloses dealings in 2 companies, chiefly Processa Pharmaceuticals, Inc. and Alimera Sciences Inc. Between 9 January 2023 and 30 April 2026, the trades on record add up to 5 filings.

No open-market sale appears; the market trades are 3 purchases worth €15k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 2 share grants. In 2026 alone, the filings show 3 purchases and no sales.

In size, the median ticket on the buying side is €5,023. Clusters matter here: 3 out of 3 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 0% of cases, with a median move of -19.8%. They describe history only and say nothing certain about the share price ahead.

On 1 May 2026 came the latest disclosure, an open-market purchase for €5,023 in Processa Pharmaceuticals, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 1 day. US insiders must file a Form 4 within two business days of a trade. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.